Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Bagi Jana

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

Original languageEnglish
Pages (from-to)540-542
Number of pages3
JournalCommunity Oncology
Volume7
Issue number12
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

docetaxel
Castration
Prednisone
Disease-Free Survival
Prostatic Neoplasms
Hormones
Therapeutics
taxane
cabazitaxel

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer. / Jana, Bagi.

In: Community Oncology, Vol. 7, No. 12, 12.2010, p. 540-542.

Research output: Contribution to journalArticle

@article{322685d0db164896b81d20eef3ddbc5f,
title = "Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer",
abstract = "A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.",
author = "Bagi Jana",
year = "2010",
month = "12",
language = "English",
volume = "7",
pages = "540--542",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "12",

}

TY - JOUR

T1 - Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

AU - Jana, Bagi

PY - 2010/12

Y1 - 2010/12

N2 - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

AB - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

UR - http://www.scopus.com/inward/record.url?scp=78651246898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651246898&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 540

EP - 542

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 12

ER -